Delivery Order SPE2DB22D3501-SPE2DB25FUC74

Award Date 1/13/25
Potential Completion Date 2/4/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $41,389.63, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the company's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of 4564288200 POLIVY 140 MG VIALS to the U.S. government. The contract, valued at $40,304.38, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical and has a completion date of May 6, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,046.06, is a Firm Fixed Price Delivery Order to provide POLIVY 140 MG VIALS to support military healthcare programs. The contract has an ultimate completion date of March 17, 2025 and was awarded on February 24, 2025. This award is not designated as a set-aside contract. Amerisourcebergen...
This federal contract award, valued at $10,454.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of POLIVY 140 MG VIALS, a pharmaceutical product, with a completion date of January 29, 2024. Amerisourcebergen, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $44,092.12, is for the delivery of POLIVY 140 MG VIALS medical supplies. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This federal contract award, valued at $111,908.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the company's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999 through November 2026. This IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical...
This federal contract award, issued by the Defense Logistics Agency (DLA) Troop Support Medical, is a delivery order valued at $5,287.68 and awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price pricing type and a completion date of December 18, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) with a delivery order valued at $1,443.79. The contract has a period of performance through March 12, 2024 and is a firm fixed-price delivery order, without any set-aside designation. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,101.60, is a delivery order for pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical medical commodities. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
The U.S. government's Defense Logistics Agency (DLA) awarded a delivery order contract worth $46,528.57 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which has a firm fixed price and runs through November 2024, is for the supply of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits. AmerisourceBergen also holds a larger...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FUC74
    Delivery Order

This federal contract award, valued at $11,023.03, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which does not have a set-aside designation, is a Delivery Order for the supply of POLIVY 140 MG VIALS, with a completion date of February 4, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 4/21/25, 3:50 AM